Markets saw a volatile session with Nifty trading below the 23,800-24,000 resistance zone, though select heavyweight buying limited downsid...

Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...

The Delhi High Court has ruled against Reddy Pharmaceuticals. The court upheld a decision to remove 'Reddy' from the company's name. Reddy ...

Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...

Markets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150....

Dr Reddy's Laboratories has achieved a significant milestone. Health Canada has approved its generic semaglutide injection. This makes Dr R...

Dr Reddy's Laboratories is recalling over 8,000 bottles of Tacrolimus capsules from the US market due to a packaging error. The Hyderabad-b...

Dr Reddy's Laboratories plans to expand its presence in nutraceuticals, cell and gene therapy and new chemical entities, as well as explori...

The increased focus on vaccine production against the backdrop of COVID-19 pandemic has necessitated more vaccine- testing laboratories in ...

The company has received EIR from USFDA for its formulations manufacturing facility at Srikakulam unit II, Dr Reddy's said in a filing to B...

The audit of our formulations manufacturing plant-3 at Bachupally, Hyderabad by the USFDA has been completed today, said Dr Reddy's Lab.

Dr Reddy's Laboratories is recalling over 55,000 bottles of Amlodipine besylate and Atorvastatin calcium tablets.

Andhra Pradesh government has lifted a ban on the expansion of bulk drug manufacturing facilities imposed six years ago to curb pollution.

Two workers of the drug firm Dr Reddy's Laboratories lost their lives and two others fell unconscious in an accidental gas leak this mornin...

A gas leakage happened in the Dr Reddy's Hyderabad plant today, in which two employees of the company have lost their lives.

Senior professionals have earned enough expertise to start their own ventures at a time when the market and funding options are favourable.

Professionals in pharma and biotechnology companies are increasingly taking the plunge to set up start-ups - a trend which investors descri...